Director of the Moulder Center for Drug Discovery Research and associate dean for research in Temple’s School of Pharmacy, Abou-Gharbia is an internationally recognized leader in drug discovery. He spent 26 years at Wyeth, where he was senior vice president of Chemical and Screening Sciences, responsible for directing 500 scientists in the United States and 150 scientists in India focused on the discovery of innovative small molecule therapeutics in multiple disease areas such as neuroscience, inflammation, women’s health/bone, oncology and cardio-vascular/metabolic diseases. During his tenure at Wyeth, Abou-Gharbia’s research team contributed to the discovery of several major drugs, including Effexor, a first-in-class serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant; Mylotarg, an antibody-targeted anti-cancer agent; Tygacil, a broad-spectrum antibiotic; Pristiq, a second generation SNRI for treatment of depression and Torisel, a cell cycle inhibitor for treatment of renal cell carcinoma. The holder of more than 350 worldwide patents, Abou-Gharbia joined Temple to establish the Moulder Center in 2008.
Abou-Gharbia has expertise in the pharmaceutical industry, drug discovery and medicinal chemistry.